Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature

Abstract

Triple-negative breast cancers (TNBCs) are aggressive tumors that are more common in young women, African American populations, and those with hereditary mutations. These tumors are notable for their high recurrence rate and predilection for chemoresistance. The goal of this narrative review is to describe the current treatment options for patients diagnosed with TNBC and to review the studies that have put forward these recommendations. We searched PubMed and Cochrane databases for free full-text, English-language studies published within the last several years pertaining to the search items "triple negative breast cancer" and "treatment". We included clinical trials and retrospective reviews that had clear designs and assessed their findings against a gold standard or placebo and included evidence of overall response and/or survival outcomes.Patients with early-stage (I-III) TNBC still benefit from treatment with chemotherapeutic regimens involving anthracyclines, taxanes, and antimetabolites. Platinum-based therapies have been shown to improve the overall pathologic complete response (pCR), but there is conflicting evidence with regard to their contribution to disease-free survival (DFS) and overall survival (OS), even with the addition of a poly (ADP-ribose) polymerase (PARP) inhibitor. Patients with residual disease after neoadjuvant chemotherapy and surgical intervention have shown a significant improvement in OS when treated with adjuvant capecitabine. The high mutation burden in metastatic TNBC (mTNBC) allows for targeted therapies and immune checkpoint inhibitors. mTNBCs that express programmed death ligand-1 (PD-L1) receptors may achieve improved response and survival if their regimen includes a monoclonal antibody. Antibody-drug conjugates (ADCs) can deliver high doses of chemotherapy and significantly impact survival in mTNBC regardless of the level of biomarkers expressed by the tumor cells. PARP inhibitors significantly improve survival in newly diagnosed, treatment-naive mTNBC, but have shown mixed results in patients with a history of previous therapy. PARP inhibitors may also target patients with somatic breast cancer (BRCA) and partner and localizer of BRCA-2 (PALB2) mutations, which would allow for more options in this subset of patients. While other rare targets have shown mixed results, the future of treatment may lie in antiandrogen therapy or the development of cancer vaccinations that may increase the immunogenicity of the tumor environment.The management of TNBC includes treatment with multimodal chemotherapy, immune checkpoint inhibitors, and ADCs. The optimal approach depends on a multitude of factors, which include the stage of the tumor, its unique mutational burden, comorbid conditions, and the functional status of the patient. Physicians should be familiar with the advantages and disadvantages of each therapy in order to appropriately counsel and guide their patients.

The obesity-breast cancer link: a multidisciplinary perspective

“…While TNBC accounts for only 15-20% of breast cancers, this intrinsic subtype is particularly aggressive, more likely to metastasize, and due in part to the lack of targeted therapies, results in worse clinical outcomes including greater recurrence and lower rates of overall survival [12]. Breast cancer, particularly TNBC, is a heterogeneous disease, hence transcriptomic signatures have been developed to further stratify these cancers.…”

Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review

“…Although preclinical studies have demonstrated promising results of cancer vaccines in TNBC, their clinical translation, safety, and efficacy have yet to be determined [ 11 , 20 , 21 ]. Thus, we aimed to systematically review the literature to provide a comprehensive update on the efficacy and safety of various vaccines against TNBC in the clinical setting.…”

Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker

“…TNBC accounts for 15-20% of all invasive breast cancer patients (4). 13.1 per 100,000 new TNBC cases among women were reported in 2021 around the world (5). 10.6% (22,375) of breast cancer cases were determined as TNBC in 2018 in Turkey (6).…”